Clinical Trial Update: Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating SGLT2 inhibitors for effects on heart and kidneys in Fabry disease patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Snippet

Sponsor: Albina Nowak, MD | Conditions: Fabry Disease | Phase 2 | Status: UNKNOWN